BNP PARIBAS ASSET MANAGEMENT Holding S.A. Raises Stock Position in Pulmonx Co. (NASDAQ:LUNG)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Pulmonx Co. (NASDAQ:LUNG) by 5.2% during the 3rd quarter, Holdings Channel.com reports. The fund owned 1,114,297 shares of the company’s stock after acquiring an additional 55,279 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Pulmonx were worth $9,238,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Squarepoint Ops LLC raised its stake in Pulmonx by 261.2% during the 2nd quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock valued at $916,000 after purchasing an additional 104,432 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in shares of Pulmonx during the second quarter valued at approximately $477,000. GSA Capital Partners LLP purchased a new position in shares of Pulmonx in the third quarter worth $537,000. Cubist Systematic Strategies LLC boosted its position in shares of Pulmonx by 141.6% during the second quarter. Cubist Systematic Strategies LLC now owns 109,105 shares of the company’s stock worth $692,000 after acquiring an additional 63,945 shares during the last quarter. Finally, Sofinnova Investments Inc. purchased a new position in Pulmonx during the second quarter valued at $382,000. Institutional investors own 91.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Canaccord Genuity Group increased their price objective on shares of Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Wells Fargo & Company dropped their price target on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. Finally, Stifel Nicolaus reduced their price objective on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.67.

Insiders Place Their Bets

In other Pulmonx news, insider Geoffrey Beran Rose sold 4,586 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total value of $30,726.20. Following the completion of the sale, the insider now owns 295,433 shares of the company’s stock, valued at $1,979,401.10. This trade represents a 1.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $6.52, for a total value of $130,400.00. Following the transaction, the director now owns 1,091,974 shares of the company’s stock, valued at $7,119,670.48. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,351 shares of company stock valued at $361,494 over the last three months. 5.70% of the stock is owned by company insiders.

Pulmonx Stock Up 5.8 %

Shares of NASDAQ LUNG opened at $6.79 on Monday. The stock has a market capitalization of $268.12 million, a price-to-earnings ratio of -4.62 and a beta of 0.68. Pulmonx Co. has a 12-month low of $5.46 and a 12-month high of $14.84. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The firm’s 50-day moving average price is $7.07 and its 200-day moving average price is $7.11.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. The business had revenue of $20.39 million during the quarter, compared to analyst estimates of $20.39 million. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. During the same period last year, the company earned ($0.39) EPS. On average, equities research analysts anticipate that Pulmonx Co. will post -1.53 EPS for the current fiscal year.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.